Approval · Notice of Compliance 17809 · 2016
PLAVIX: Notice of Compliance 17809
Issued February 29, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17809
- Date
- February 29, 2016
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Add a new contraindications in patients who are taking repaglinide
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PLAVIX | Not yet assigned | — |
Medicinal ingredients
- CLOPIDOGREL BISULFATE 75 MG per TAB
- CLOPIDOGREL BISULFATE 300 MG per TAB